Median Technologies (ALMDT) announced today that it will be presenting an abstract at the 2022 ASCO Annual Meeting, June 3-7, McCormick Place, Chicago, IL, USA (exhibition dates: June 4-6).
Read moreWith Imaging Lab, Median will provide biopharmaceutical companies with new decision-making tools for clinical trials by leveraging images with data mining and Artificial Intelligence (AI) technologies from iBiopsy® and radiomics. Imaging Lab’s solutions will support the pharmaceutical industry’s paradigm shift towards therapies targeting patients with early-stage cancers. The Imaging Lab team will be exhibiting at the ASCO Annual Conference in Chicago, June 3-7, 2022, Median’s booth #2098.
Read moreMedian has received the FDA’s feedback following the 513(g) regulatory submission for its iBiopsy® LCS CADe/CADx Software as Medical Device. Median will proceed through a 510(k) submission to obtain an FDA device clearance and market authorization, targeted for end 2023. On May 2, 2022, Median initiated a Q-submission process, composed of several submissions, to request feedback from the FDA on various topics such as the pivotal study protocols.
Read moreRecord high revenue of €5.7 million in Q1 2022, up 9.2% compared with Q1 2021 – Further growth in the order backlog to €62.3 million as of March 31, 2022, up 18.4% compared with March 31, 2021- Revenue of €20.5 million as of December 31, 2021, up 52.4% compared to December 31, 2020 – Cash and cash equivalents of €33.1 million as of March 31, 2022
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]